Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 3, 2024BMC MedicineOpen Access

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAna‐Lucia MayénMSMirna SabraEAElom K. Aglago

Discussion

Loading...

Member takes

Overview

Prospective cohort study shows elevated overall and cardiovascular mortality in adults with hepatic steatosis or metabolic dysfunction, highlighting the critical risks of fatty liver disease.

Key Points

  • Elevated hepatic steatosis and metabolic dysfunction significantly increase the risk of all-cause and cardiovascular mortality, driven by severe liver fat accumulation.
  • A fatty liver index of 60 or higher elevated cardiovascular mortality risk by more than twofold (HR = 2.06), with 1,997 total deaths recorded across 15,784 participants.
  • Prospective cohort analysis using multivariable Cox proportional hazards models evaluated associations across a median follow-up period of 15.6 years in the multinational cohort.

Cite This Study

Mayén et al. (2024) studied this question.

synapsesocial.com/papers/68e665f2b6db6435875f20dahttps://doi.org/10.1186/s12916-024-03366-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up2024 · 74 citations
  2. 2Association between metabolic score of visceral fat and all-cause mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a follow-up study based on NHANES III (1988–1994)2025 · 1 citations
  3. 3The association of fatty liver index and metabolic syndrome with cardiovascular outcomes, liver-related mortality, and all-cause mortality: A nationwide cohort study2024
  4. 4Liver fibrosis index and mortality in metabolic dysfunction–associated steatotic liver disease: a Korean cohort study2025
  5. 5Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease2024 · 21 citations